Today we presented the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma at the 65th American Society of Hematology Annual Meeting and Exposition, and declared 12 mg as the HPN217 recommended Phase 2 dose View full release here: https://lnkd.in/dbh3GJta $HARP #immunooncology #TCell #cancer #biotech #ASH2023 #RP2D
